{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:15:00Z","timestamp":1778591700049,"version":"3.51.4"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11929-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:43:31Z","timestamp":1778589811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aspirin as a neuroprotective scaffold in Alzheimer\u2019s disease: inflammation, oxidative stress, and future directions"],"prefix":"10.1007","volume":"53","author":[{"given":"Kailash","family":"S","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokulavani","family":"L","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pandi Prabha","family":"S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"C","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"4","key":"11929_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.14283\/jpad.2023.109","volume":"10","author":"M Kiraly","year":"2023","unstructured":"Kiraly M, Foss JF, Giordano T (2023) Neuroinflammation, its role in Alzheimer\u2019s disease and therapeutic strategies. J Prev Alzheimers Dis 10(4):686\u2013698. https:\/\/doi.org\/10.14283\/jpad.2023.109","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"11929_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/ijmm.2023.5314","volume":"52","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zhang X, Zhang R, Wang Z, Gan J, Gao Q, Yang L, Xu P, Jiang X (2023) Inflammatory signaling pathways in the treatment of Alzheimer\u2019s disease with inhibitors, natural products and metabolites: a comprehensive review. Int J Mol Med 52(5):111. https:\/\/doi.org\/10.3892\/ijmm.2023.5314","journal-title":"Int J Mol Med"},{"issue":"5","key":"11929_CR3","doi-asserted-by":"publisher","first-page":"e84057","DOI":"10.7759\/cureus.84057","volume":"17","author":"E Bornemann","year":"2025","unstructured":"Bornemann E, Kamma HK, Alabbas M, Elashahab M, Abid N, Manaye S, Cheran K, Murthy C, Giva S, Penumetcha SS (2025) The effect of chronic inflammation and oxidative stress on Alzheimer\u2019s disease progression: a systematic review. Cureus 17(5):e84057. https:\/\/doi.org\/10.7759\/cureus.84057","journal-title":"Cureus"},{"issue":"22","key":"11929_CR4","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.3390\/ijms252211941","volume":"25","author":"F Roveta","year":"2024","unstructured":"Roveta F, Bonino L, Piella EM, Rainero I, Rubino E (2024) Neuroinflammatory biomarkers in Alzheimer\u2019s disease: from pathophysiology to clinical implications. Int J Mol Sci 25(22):11941. https:\/\/doi.org\/10.3390\/ijms252211941","journal-title":"Int J Mol Sci"},{"issue":"4","key":"11929_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/neuroglia5040029","volume":"5","author":"S Shah","year":"2024","unstructured":"Shah S, Jain H (2024) Microglia-associated neuroinflammation in Alzheimer\u2019s disease and its therapeutic potential. Neuroglia 5(4):452\u2013466. https:\/\/doi.org\/10.3390\/neuroglia5040029","journal-title":"Neuroglia"},{"key":"11929_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1575453","volume":"19","author":"J Han","year":"2025","unstructured":"Han J, Zhang Z, Zhang P, Yu Q, Cheng Q, Lu Z, Zong S (2025) The roles of microglia and astrocytes in neuroinflammation of Alzheimer\u2019s disease. Front Neurosci 19:1575453. https:\/\/doi.org\/10.3389\/fnins.2025.1575453","journal-title":"Front Neurosci"},{"key":"11929_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9:42. https:\/\/doi.org\/10.1186\/s40035-020-00221-2","journal-title":"Transl Neurodegener"},{"key":"11929_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12979-024-00445-0","volume":"21","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Yang G, Luo Y, Jiang L, Chi H, Tian G (2024) Neuroinflammation in Alzheimer\u2019s disease: insights from peripheral immune cells. Immun Ageing 21:38. https:\/\/doi.org\/10.1186\/s12979-024-00445-0","journal-title":"Immun Ageing"},{"key":"11929_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00828-x","volume":"20","author":"MR Duggan","year":"2025","unstructured":"Duggan MR, Morgan DG, Price BR, Rajbanshi B, Martin-Pe\u00f1a A, G\u00e1mez Tansey M, Walker KA (2025) Immune modulation to treat Alzheimer\u2019s disease. Mol Neurodegener 20:39. https:\/\/doi.org\/10.1186\/s13024-025-00828-x","journal-title":"Mol Neurodegener"},{"key":"11929_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1412-9","volume":"16","author":"DJ Finneran","year":"2019","unstructured":"Finneran DJ, Nash KR (2019) Neuroinflammation and fractalkine signaling in Alzheimer\u2019s disease. J Neuroinflammation 16:30. https:\/\/doi.org\/10.1186\/s12974-019-1412-9","journal-title":"J Neuroinflammation"},{"key":"11929_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, van der Flier WM, Jessen F et al (2025) Neuroinflammation in Alzheimer disease. Nat Rev Immunol 25:321\u2013352. https:\/\/doi.org\/10.1038\/s41577-024-01104-7","journal-title":"Nat Rev Immunol"},{"key":"11929_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P et al (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46:1\u201317. https:\/\/doi.org\/10.1007\/s10753-022-01721-1","journal-title":"Inflammation"},{"issue":"4","key":"11929_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","volume":"57","author":"S Castro-Gomez","year":"2024","unstructured":"Castro-Gomez S, Heneka MT (2024) Innate immune activation in neurodegenerative diseases. Immunity 57(4):790\u2013814. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.010","journal-title":"Immunity"},{"issue":"4","key":"11929_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4103\/1673-5374.353484","volume":"18","author":"ZZ Si","year":"2023","unstructured":"Si ZZ, Zou CJ, Mei X, Li XF, Luo H, Shen Y, Hu J, Li XX, Wu L, Liu Y (2023) Targeting neuroinflammation in Alzheimer\u2019s disease: from mechanisms to clinical applications. Neural Regen Res 18(4):708\u2013715. https:\/\/doi.org\/10.4103\/1673-5374.353484","journal-title":"Neural Regen Res"},{"issue":"12","key":"11929_CR15","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/cells11121885","volume":"11","author":"Y Rajesh","year":"2022","unstructured":"Rajesh Y, Kanneganti TD (2022) Innate immune cell death in neuroinflammation and Alzheimer\u2019s disease. Cells 11(12):1885. https:\/\/doi.org\/10.3390\/cells11121885","journal-title":"Cells"},{"key":"11929_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yu Y (2023) Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J Neuroinflammation 20:165. https:\/\/doi.org\/10.1186\/s12974-023-02853-3","journal-title":"J Neuroinflammation"},{"issue":"5","key":"11929_CR17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines9050524","volume":"9","author":"IG Onyango","year":"2021","unstructured":"Onyango IG, Jauregui GV, \u010carn\u00e1 M, Bennett JP Jr, Stokin GB (2021) Neuroinflammation in Alzheimer\u2019s Disease. Biomedicines 9(5):524. https:\/\/doi.org\/10.3390\/biomedicines9050524","journal-title":"Biomedicines"},{"key":"11929_CR18","doi-asserted-by":"publisher","first-page":"739130","DOI":"10.3389\/fimmu.2021.739130","volume":"12","author":"R Zhou","year":"2021","unstructured":"Zhou R, Ji B, Kong Y, Qin L, Ren W, Guan Y, Ni R (2021) PET imaging of neuroinflammation in Alzheimer\u2019s disease. Front Immunol 12:739130. https:\/\/doi.org\/10.3389\/fimmu.2021.739130","journal-title":"Front Immunol"},{"issue":"4","key":"11929_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14(4):388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"issue":"18","key":"11929_CR20","doi-asserted-by":"publisher","first-page":"10572","DOI":"10.3390\/ijms231810572","volume":"23","author":"NF Al-Ghraiybah","year":"2022","unstructured":"Al-Ghraiybah NF, Wang J, Alkhalifa AE, Roberts AB, Raj R, Yang E, Kaddoumi A (2022) Glial cell-mediated neuroinflammation in Alzheimer\u2019s disease. Int J Mol Sci 23(18):10572. https:\/\/doi.org\/10.3390\/ijms231810572","journal-title":"Int J Mol Sci"},{"issue":"21","key":"11929_CR21","doi-asserted-by":"publisher","first-page":"12990","DOI":"10.3390\/ijms232112990","volume":"23","author":"S Merighi","year":"2022","unstructured":"Merighi S, Nigro M, Travagli A, Gessi S (2022) Microglia and Alzheimer\u2019s Disease. Int J Mol Sci 23(21):12990. https:\/\/doi.org\/10.3390\/ijms232112990","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11929_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ibra.12023","volume":"8","author":"YH Guan","year":"2022","unstructured":"Guan YH, Zhang LJ, Wang SY, Deng YD, Zhou HS, Chen DQ, Zhang LC (2022) The role of microglia in Alzheimer\u2019s disease and progress of treatment. Ibrain 8(1):37\u201347. https:\/\/doi.org\/10.1002\/ibra.12023","journal-title":"Ibrain"},{"key":"11929_CR23","doi-asserted-by":"publisher","first-page":"114754","DOI":"10.1016\/j.bcp.2021.114754","volume":"192","author":"K Takata","year":"2021","unstructured":"Takata K, Ginhoux F, Shimohama S (2021) Roles of microglia in Alzheimer\u2019s disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. Biochem Pharmacol 192:114754. https:\/\/doi.org\/10.1016\/j.bcp.2021.114754","journal-title":"Biochem Pharmacol"},{"key":"11929_CR24","doi-asserted-by":"publisher","first-page":"1201982","DOI":"10.3389\/fnagi.2023.1201982","volume":"15","author":"J Miao","year":"2023","unstructured":"Miao J, Ma H, Yang Y, Liao Y, Lin C, Zheng J, Yu M, Lan J (2023) Microglia in Alzheimer\u2019s disease: pathogenesis, mechanisms, and therapeutic potentials. Front Aging Neurosci 15:1201982. https:\/\/doi.org\/10.3389\/fnagi.2023.1201982","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"11929_CR25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A et al (2017) A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169(7):1276\u20131290e17. https:\/\/doi.org\/10.1016\/j.cell.2017.05.018","journal-title":"Cell"},{"key":"11929_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys H, Davila-Velderrain J, Peng Z et al (2019) Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature 570:332\u2013337. https:\/\/doi.org\/10.1038\/s41586-019-1195-2","journal-title":"Nature"},{"issue":"8","key":"11929_CR27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/cells12081207","volume":"12","author":"R Fujikawa","year":"2023","unstructured":"Fujikawa R, Tsuda M (2023) The functions and phenotypes of microglia in Alzheimer\u2019s disease. Cells 12(8):1207. https:\/\/doi.org\/10.3390\/cells12081207","journal-title":"Cells"},{"key":"11929_CR28","doi-asserted-by":"publisher","first-page":"749587","DOI":"10.3389\/fncel.2021.749587","volume":"15","author":"G Zhang","year":"2021","unstructured":"Zhang G, Wang Z, Hu H, Zhao M, Sun L (2021) Microglia in Alzheimer\u2019s disease: a target for therapeutic intervention. Front Cell Neurosci 15:749587. https:\/\/doi.org\/10.3389\/fncel.2021.749587","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"11929_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/cells10030540","volume":"10","author":"P Preman","year":"2021","unstructured":"Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A, Arranz AM (2021) Astrocytes in Alzheimer\u2019s disease: pathological significance and molecular pathways. Cells 10(3):540. https:\/\/doi.org\/10.3390\/cells10030540","journal-title":"Cells"},{"key":"11929_CR30","doi-asserted-by":"publisher","first-page":"619626","DOI":"10.3389\/fneur.2021.619626","volume":"12","author":"MD Monterey","year":"2021","unstructured":"Monterey MD, Wei H, Wu X, Wu JQ (2021) The Many Faces of Astrocytes in Alzheimer\u2019s Disease. Front Neurol 12:619626. https:\/\/doi.org\/10.3389\/fneur.2021.619626","journal-title":"Front Neurol"},{"key":"11929_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s12276-023-01148-0","volume":"56","author":"J Kim","year":"2024","unstructured":"Kim J, Yoo ID, Lim J et al (2024) Pathological phenotypes of astrocytes in Alzheimer\u2019s disease. Exp Mol Med 56:95\u201399. https:\/\/doi.org\/10.1038\/s12276-023-01148-0","journal-title":"Exp Mol Med"},{"key":"11929_CR32","doi-asserted-by":"publisher","first-page":"1481748","DOI":"10.3389\/fnagi.2024.1481748","volume":"16","author":"X An","year":"2024","unstructured":"An X, He J, Bi B, Wu G, Xu J, Yu W, Ren Z (2024) The role of astrocytes in Alzheimer\u2019s disease: a bibliometric analysis. Front Aging Neurosci 16:1481748. https:\/\/doi.org\/10.3389\/fnagi.2024.1481748","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"11929_CR33","doi-asserted-by":"publisher","first-page":"170228","DOI":"10.1098\/rsob.170228","volume":"7","author":"GR Frost","year":"2017","unstructured":"Frost GR, Li YM (2017) The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol 7(12):170228. https:\/\/doi.org\/10.1098\/rsob.170228","journal-title":"Open Biol"},{"key":"11929_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fnmol.2017.00427","volume":"10","author":"RE Gonz\u00e1lez-Reyes","year":"2017","unstructured":"Gonz\u00e1lez-Reyes RE, Nava-Mesa MO, Vargas-S\u00e1nchez K, Ariza-Salamanca D, Mora-Mu\u00f1oz L (2017) Involvement of astrocytes in Alzheimer\u2019s disease from a neuroinflammatory and oxidative stress perspective. Front Mol Neurosci 10:427. https:\/\/doi.org\/10.3389\/fnmol.2017.00427","journal-title":"Front Mol Neurosci"},{"key":"11929_CR35","doi-asserted-by":"publisher","first-page":"870085","DOI":"10.3389\/fnmol.2022.870085","volume":"15","author":"D Labib","year":"2022","unstructured":"Labib D, Wang Z, Prakash P et al (2022) Proteomic alterations and novel markers of neurotoxic reactive astrocytes in human iPSC models. Front Mol Neurosci 15:870085. https:\/\/doi.org\/10.3389\/fnmol.2022.870085","journal-title":"Front Mol Neurosci"},{"key":"11929_CR36","doi-asserted-by":"publisher","first-page":"899251","DOI":"10.3389\/fncel.2022.899251","volume":"16","author":"LA Hulshof","year":"2022","unstructured":"Hulshof LA, van Nuijs D, Hol EM, Middeldorp J (2022) The Role of Astrocytes in Synapse Loss in Alzheimer\u2019s Disease: A Systematic Review. Front Cell Neurosci 16:899251. https:\/\/doi.org\/10.3389\/fncel.2022.899251","journal-title":"Front Cell Neurosci"},{"issue":"6286","key":"11929_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352(6286):712\u2013716. https:\/\/doi.org\/10.1126\/science.aad8373","journal-title":"Science"},{"key":"11929_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-07704-3_5","volume-title":"Bioinformatics and Biomedical Engineering. IWBBIO 2022. Lecture Notes in Computer Science()","author":"S Pal","year":"2022","unstructured":"Pal S, Melnik R (2022) The Role of Astrocytes in Alzheimer\u2019s Disease Progression. In: Rojas I, Valenzuela O, Rojas F, Herrera LJ, Ortu\u00f1o F (eds) Bioinformatics and Biomedical Engineering. IWBBIO 2022. Lecture Notes in Computer Science(), vol 13346. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-031-07704-3_5"},{"key":"11929_CR39","doi-asserted-by":"publisher","first-page":"742408","DOI":"10.3389\/fnagi.2022.742408","volume":"14","author":"MB Abubakar","year":"2022","unstructured":"Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, Khoo CS, Kumar J (2022) Alzheimer\u2019s Disease: An Update and Insights Into Pathophysiology. Front Aging Neurosci 14:742408. https:\/\/doi.org\/10.3389\/fnagi.2022.742408","journal-title":"Front Aging Neurosci"},{"key":"11929_CR40","doi-asserted-by":"publisher","first-page":"1070277","DOI":"10.3389\/fphar.2022.1070277","volume":"13","author":"U H\u00f6fing","year":"2022","unstructured":"H\u00f6fing U, Le Gouellec A, Claria J, Serhan CN, Perretti M, Patel HB et al (2022) Characterization of the acetylation of cyclooxygenase-2 and its role in aspirin-triggered mediators. Front Pharmacol 13:1070277. https:\/\/doi.org\/10.3389\/fphar.2022.1070277","journal-title":"Front Pharmacol"},{"key":"11929_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fimmu.2017.00261","volume":"8","author":"AP Cadavid","year":"2017","unstructured":"Cadavid AP (2017) Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol 8:261. https:\/\/doi.org\/10.3389\/fimmu.2017.00261","journal-title":"Front Immunol"},{"issue":"1","key":"11929_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bph.15966","volume":"180","author":"C Patrono","year":"2023","unstructured":"Patrono C (2023) Fifty years with aspirin and platelets. Br J Pharmacol 180(1):25\u201343. https:\/\/doi.org\/10.1111\/bph.15966","journal-title":"Br J Pharmacol"},{"issue":"4","key":"11929_CR43","doi-asserted-by":"publisher","first-page":"e0283163","DOI":"10.1371\/journal.pone.0283163","volume":"18","author":"KM Rood","year":"2023","unstructured":"Rood KM, Patel N, DeVengencie IM, Quinn JP, Gowdy KM, Costantine MM et al (2023) Aspirin modulates production of pro-inflammatory and pro-resolving mediators in endothelial cells. PLoS ONE 18(4):e0283163. https:\/\/doi.org\/10.1371\/journal.pone.0283163","journal-title":"PLoS ONE"},{"key":"11929_CR44","doi-asserted-by":"publisher","first-page":"781889","DOI":"10.3389\/fphar.2022.781889","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li Z, Fan M, Jin W (2022) Lipoxins in the nervous system: brighter prospects for neuroprotection. Front Pharmacol 13:781889. https:\/\/doi.org\/10.3389\/fphar.2022.781889","journal-title":"Front Pharmacol"},{"issue":"4","key":"11929_CR45","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s12035-015-9544-0","volume":"53","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wang X, Hjorth E et al (2016) Pro-resolving lipid mediators improve neuronal survival and increase A\u03b242 phagocytosis. Mol Neurobiol 53(4):2733\u20132749. https:\/\/doi.org\/10.1007\/s12035-015-9544-0","journal-title":"Mol Neurobiol"},{"issue":"1","key":"11929_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1021\/acsptsci.9b00097","volume":"3","author":"T Fu","year":"2020","unstructured":"Fu T, Mohan M, Brennan EP, Woodman OL, Godson C, Kantharidis P, Ritchie RH, Qin CX (2020) Therapeutic potential of Lipoxin A4 in chronic inflammation: focus on cardiometabolic disease. ACS Pharmacol Transl Sci 3(1):43\u201355. https:\/\/doi.org\/10.1021\/acsptsci.9b00097","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"11929_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-95","volume":"8","author":"L Jiang","year":"2011","unstructured":"Jiang L, Zhang J, Wang Y et al (2011) Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-\u03baB and MAPKs in BV-2 microglial cells. J Neuroinflammation 8(1):95. https:\/\/doi.org\/10.1186\/1742-2094-8-95","journal-title":"J Neuroinflammation"},{"issue":"6","key":"11929_CR48","doi-asserted-by":"publisher","first-page":"834","DOI":"10.7150\/ijms.40959","volume":"17","author":"A Jorda","year":"2020","unstructured":"Jorda A, Aldasoro M, Aldasoro C, Guerra-Ojeda S, Iradi A, Vila JM, Campos-Campos J, Valles SL (2020) Action of low doses of aspirin in inflammation and oxidative stress induced by A\u03b2\u2081\u208b\u2084\u2082 on astrocytes in primary culture. Int J Med Sci 17(6):834\u2013843. https:\/\/doi.org\/10.7150\/ijms.40959","journal-title":"Int J Med Sci"},{"issue":"4","key":"11929_CR49","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/ph17040437","volume":"17","author":"O Werz","year":"2024","unstructured":"Werz O, Stettler H, Theurer C, Seibel J (2024) The 125th anniversary of aspirin\u2014the story continues. Pharmaceuticals Basel 17(4):437. https:\/\/doi.org\/10.3390\/ph17040437","journal-title":"Pharmaceuticals Basel"},{"issue":"2","key":"11929_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.31351\/vol31iss2pp14-32","volume":"31","author":"AI Hamdan","year":"2022","unstructured":"Hamdan AI (2022) Aspirin derivatives exploration: a review on comparison of biological activities and chemical modifications. Baghdad J Pharm Sci 31(2):14\u201332. https:\/\/doi.org\/10.31351\/vol31iss2pp14-32","journal-title":"Baghdad J Pharm Sci"},{"issue":"5","key":"11929_CR51","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.118909","volume":"11","author":"A Rezabakhsh","year":"2021","unstructured":"Rezabakhsh A, Mahmoodpoor A, Soleimanpour M, Shahsavarinia K, Soleimanpour H (2021) Clinical applications of aspirin as a multi-potent drug beyond cardiovascular implications: a proof of concept for anesthesiologists\u2014a narrative review. Anesth Pain Med 11(5):e118909. https:\/\/doi.org\/10.5812\/aapm.118909","journal-title":"Anesth Pain Med"},{"key":"11929_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-023-03243-0","volume":"23","author":"E Khoshbin","year":"2023","unstructured":"Khoshbin E, Salehi R, Behroozi R et al (2023) The effect of low-dose aspirin on aspirin triggered lipoxin, interleukin 1 beta, and prostaglandin E2 levels in periapical fluid: a double-blind randomized clinical trial. BMC Oral Health 23:530. https:\/\/doi.org\/10.1186\/s12903-023-03243-0","journal-title":"BMC Oral Health"},{"issue":"30","key":"11929_CR53","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1523\/JNEUROSCI.0054-18.2018","volume":"38","author":"S Chandra","year":"2018","unstructured":"Chandra S, Jana M, Pahan K (2018) Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer\u2019s disease via PPAR\u03b1. J Neurosci 38(30):6682\u20136699. https:\/\/doi.org\/10.1523\/JNEUROSCI.0054-18.2018","journal-title":"J Neurosci"},{"key":"11929_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13195-022-01017-4","volume":"14","author":"TNM Nguyen","year":"2022","unstructured":"Nguyen TNM, Louwersheimer E, Jansen I et al (2022) Long-term, low-dose acetylsalicylic use shows protective association with dementia in two large population-based cohorts. Alz Res Ther 14:102. https:\/\/doi.org\/10.1186\/s13195-022-01017-4","journal-title":"Alz Res Ther"},{"issue":"2","key":"11929_CR55","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3233\/JAD-220901","volume":"91","author":"MP Gorenflo","year":"2022","unstructured":"Gorenflo MP, Davis PB, Kendall EK, Olaker VR, Kaelber DC, Xu R (2022) Association of Aspirin use with reduced risk of developing Alzheimer\u2019s disease in elderly ischemic stroke patients: a retrospective cohort study. J Alzheimers Dis 91(2):697\u2013704. https:\/\/doi.org\/10.3233\/JAD-220901","journal-title":"J Alzheimers Dis"},{"key":"11929_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00228-003-0618-y","volume":"59","author":"SE Nilsson","year":"2003","unstructured":"Nilsson SE, Johansson B, Takkinen S et al (2003) Does aspirin protect against Alzheimer\u2019s dementia? A study in a Swedish population-based sample aged\u2009\u2265\u200980 years. Eur J Clin Pharmacol 59:313\u2013319. https:\/\/doi.org\/10.1007\/s00228-003-0618-y","journal-title":"Eur J Clin Pharmacol"},{"key":"11929_CR57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","volume":"17","author":"BM Bettcher","year":"2021","unstructured":"Bettcher BM, Tansey MG, Doroth\u00e9e G et al (2021) Peripheral and central immune system crosstalk in Alzheimer disease \u2014 a research prospectus. Nat Rev Neurol 17:689\u2013701. https:\/\/doi.org\/10.1038\/s41582-021-00549-x","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"11929_CR58","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1212\/WNL.0000000000009277","volume":"95","author":"J Ryan","year":"2020","unstructured":"Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, Nelson MR, Chong TTJ, Williamson JD, Ward SA, Lockery JE, Orchard SG, Trevaks R, Kirpach B, Newman AB, Ernst ME, McNeil JJ, Shah RC, ASPREE Investigator Group (2020) Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology 95(3):e320\u2013e331. https:\/\/doi.org\/10.1212\/WNL.0000000000009277","journal-title":"Neurology"},{"issue":"3","key":"11929_CR59","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JAD-220787","volume":"92","author":"P Ding","year":"2023","unstructured":"Ding P, Gorenflo MP, Zhu X, Xu R (2023) Aspirin use and risk of Alzheimer\u2019s disease: a 2-sample Mendelian randomization study. J Alzheimers Dis 92(3):989\u20131000. https:\/\/doi.org\/10.3233\/JAD-220787","journal-title":"J Alzheimers Dis"},{"key":"11929_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.578071","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Chen M, Li J, Li H, Zhou Y, Jiang S (2021) Aspirin use on incident dementia and mild cognitive decline: a systematic review and meta-analysis. Front Aging Neurosci 12:578071. https:\/\/doi.org\/10.3389\/fnagi.2020.578071","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"11929_CR61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/futurepharmacol3010011","volume":"3","author":"EH Thong","year":"2023","unstructured":"Thong EH, Lee ECY, Yun C\u2013Y, Li TYW, Sia C\u2013H (2023) Aspirin therapy, cognitive impairment, and dementia \u2014 a review. Future Pharmacol 3(1):144\u2013161. https:\/\/doi.org\/10.3390\/futurepharmacol3010011","journal-title":"Future Pharmacol"},{"issue":"1","key":"11929_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/1673-5374.374137","volume":"19","author":"J Chu","year":"2024","unstructured":"Chu J, Zhang W, Liu Y, Gong B, Ji W, Yin T, Gao C, Liangwen D, Hao M, Chen C, Zhuang J, Gao J, Yin Y (2024) Biomaterials\u2011based anti\u2011inflammatory treatment strategies for Alzheimer\u2019s disease. Neural Regen Res 19(1):100\u2013115. https:\/\/doi.org\/10.4103\/1673-5374.374137","journal-title":"Neural Regen Res"},{"issue":"6","key":"11929_CR63","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.apsb.2022.01.002","volume":"12","author":"Z Ju","year":"2022","unstructured":"Ju Z, Li H, Xu J, Howell DC, Li Z, Chen F\u2013E (2022) Recent development on COX\u20132 inhibitors as promising anti\u2013inflammatory agents: the past 10 years. Acta Pharm Sin B 12(6):2790\u20132807. https:\/\/doi.org\/10.1016\/j.apsb.2022.01.002","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"11929_CR64","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1039\/D1MD00280E","volume":"13","author":"M Ahmadi","year":"2022","unstructured":"Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K (2022) Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med Chem 13(5):471\u2013496. https:\/\/doi.org\/10.1039\/D1MD00280E","journal-title":"RSC Med Chem"},{"issue":"20","key":"11929_CR65","doi-asserted-by":"publisher","first-page":"17446","DOI":"10.1021\/acsomega.3c00692","volume":"8","author":"S Chahal","year":"2023","unstructured":"Chahal S, Rani P, Kiran, Sindhu J, Joshi G, Ganesan A, Kalyaanamoorthy S, Mayank, Kumar P, Singh R, Negi A (2023) Design and development of COX-II inhibitors: current scenario and future perspective. ACS Omega 8(20):17446\u201317498. https:\/\/doi.org\/10.1021\/acsomega.3c00692","journal-title":"ACS Omega"},{"issue":"12","key":"11929_CR66","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.3390\/molecules28124668","volume":"28","author":"T Pan","year":"2023","unstructured":"Pan T, He M, Deng L, Li J, Fan Y, Hao X, Mu S (2023) Design, synthesis and evaluation of new 1,3-dihydro-2H-indolin-2-one derivatives as COX-2 inhibitors. Molecules 28(12):4668. https:\/\/doi.org\/10.3390\/molecules28124668","journal-title":"Molecules"},{"issue":"7","key":"11929_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070827","volume":"15","author":"AA El-Malah","year":"2022","unstructured":"El-Malah AA, Gineinah MM, Deb PK, Khayyat AN, Bansal M, Venugopala KN, Aljahdali AS (2022) Selective COX-2 inhibitors: road from success to controversy and the quest for repurposing. Pharmaceuticals (Basel) 15(7):827. https:\/\/doi.org\/10.3390\/ph15070827","journal-title":"Pharmaceuticals (Basel)"},{"key":"11929_CR68","doi-asserted-by":"publisher","first-page":"30647","DOI":"10.1039\/D4RA04686B","volume":"14","author":"NA Khalil","year":"2024","unstructured":"Khalil NA, Ahmed EM, Tharwat T, Mahmoud Z (2024) NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead. RSC Adv 14:30647\u201330661. https:\/\/doi.org\/10.1039\/D4RA04686B","journal-title":"RSC Adv"},{"issue":"9","key":"11929_CR69","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3390\/microorganisms11092247","volume":"11","author":"SZ Al-Shawwa","year":"2023","unstructured":"Al-Shawwa SZ, Alshamsan A, Alqurashi Y, Al-Dhawi A, Badran MM, Nasrullah M, Alshehri SM, Al-Omar MA (2023) Celecoxib-loaded cubosomal nanoparticles as an oral delivery system: improving bioavailability and targeting. Microorganisms 11(9):2247. https:\/\/doi.org\/10.3390\/microorganisms11092247","journal-title":"Microorganisms"},{"issue":"12","key":"11929_CR70","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.1021\/acs.jmedchem.4c00838","volume":"67","author":"V Lembo","year":"2024","unstructured":"Lembo V, Bottegoni G (2024) Systematic investigation of dual-target-directed ligands (DTDLs). J Med Chem 67(12):10374\u201310385. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00838","journal-title":"J Med Chem"},{"issue":"1","key":"11929_CR71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40199-019-00323-x","volume":"28","author":"OI Kulikova","year":"2020","unstructured":"Kulikova OI, Stvolinsky SL, Migulin VA, Andreeva LA, Nagaev IY, Lopacheva OM, Kulichenkova KN, Lopachev AV, Trubitsina IE, Fedorova TN (2020) A new derivative of acetylsalicylic acid and carnosine: synthesis, physical and chemical properties, biological activity. DARU J Pharm Sci 28(1):119\u2013130. https:\/\/doi.org\/10.1007\/s40199-019-00323-x","journal-title":"DARU J Pharm Sci"},{"issue":"3","key":"11929_CR72","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/2045-9912.266990","volume":"9","author":"AS Zhao","year":"2019","unstructured":"Zhao AS, Zou D, Wang HH, Han X, Yang P, Huang N (2019) Hydrogen sulphide-releasing aspirin enhances cell capabilities of anti-oxidative lesions and anti-inflammation. Med Gas Res 9(3):145\u2013152. https:\/\/doi.org\/10.4103\/2045-9912.266990","journal-title":"Med Gas Res"},{"issue":"4","key":"11929_CR73","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1021\/ml300002m","volume":"3","author":"R Kodela","year":"2012","unstructured":"Kodela R, Chattopadhyay M, Kashfi K (2012) NOSH-aspirin: a novel nitric oxide\u2013hydrogen sulfide-releasing hybrid; a new class of anti-inflammatory pharmaceuticals. ACS Med Chem Lett 3(4):332\u2013336. https:\/\/doi.org\/10.1021\/ml300002m","journal-title":"ACS Med Chem Lett"},{"issue":"23","key":"11929_CR74","doi-asserted-by":"publisher","first-page":"9017","DOI":"10.3390\/ijms21239017","volume":"21","author":"AC Ruberte","year":"2020","unstructured":"Ruberte AC, Pi\u00f1ol M, Sol\u00e0 M, Llobera M, P\u00e9rez M, Bertr\u00e1n E et al (2020) New formulation of a methylseleno-aspirin analog with anticancer activity. Int J Mol Sci 21(23):9017. https:\/\/doi.org\/10.3390\/ijms21239017","journal-title":"Int J Mol Sci"},{"issue":"17","key":"11929_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25173849","volume":"25","author":"M Salla","year":"2020","unstructured":"Salla M, Pandya V, Bhullar KS, Kerek E, Wong YF, Losch R, Ou J, Aldawsari FS, Velazquez-Martinez C, Thiesen A, Dyck JRB, Hubbard BP, Baksh S (2020) Resveratrol and resveratrol-aspirin hybrid compounds as potent intestinal anti-inflammatory and anti-tumor drugs. Molecules 25(17):3849. https:\/\/doi.org\/10.3390\/molecules25173849","journal-title":"Molecules"},{"issue":"16","key":"11929_CR76","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1021\/acs.jmedchem.5b00536","volume":"58","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Fu J, Shurlknight KL, Soroka DN, Hu Y, Chen X, Sang S (2015) Novel resveratrol\u2013based aspirin prodrugs: synthesis, metabolism, and anticancer activity. J Med Chem 58(16):6494\u20136506. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00536","journal-title":"J Med Chem"},{"key":"11929_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105466","volume":"117","author":"AM Srour","year":"2021","unstructured":"Srour AM, Panda SS, Mostafa A, Fayad W, El\u2011Manawaty MA, Soliman AAF, Moatasim Y, El Taweel A, Abdelhameed MF, Bekheit MS, Ali MA, Girgis AS (2021) Synthesis of aspirin\u2011curcumin mimic conjugates of potential antitumor and anti\u2011SARS\u2011CoV\u20112 properties. Bioorg Chem 117:105466. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105466","journal-title":"Bioorg Chem"},{"key":"11929_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658840","volume":"12","author":"RI Ja\u00e9n","year":"2021","unstructured":"Ja\u00e9n RI, S\u00e1nchez-Garc\u00eda S, Fern\u00e1ndez-Velasco M, Bosc\u00e1 L, Prieto P (2021) Resolution-based therapies: the potential of lipoxins to treat human diseases. Front Immunol 12:658840. https:\/\/doi.org\/10.3389\/fimmu.2021.658840","journal-title":"Front Immunol"},{"issue":"15","key":"11929_CR79","doi-asserted-by":"publisher","first-page":"10457","DOI":"10.1021\/acs.jmedchem.1c00987","volume":"64","author":"M Rossi","year":"2021","unstructured":"Rossi M, D\u2019Annessa I, Trabocchi A, Mangiatordi GF, Nicolotti O (2021) Sustainable drug discovery of multi-target-directed ligands: a medicinal chemistry perspective. J Med Chem 64(15):10457\u201310479. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00987","journal-title":"J Med Chem"},{"key":"11929_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.837649","volume":"14","author":"C-X Gong","year":"2022","unstructured":"Gong C-X, Liu F, Grundke-Iqbal I, Iqbal K (2022) Multi-targets: an unconventional drug development strategy for Alzheimer\u2019s disease. Front Aging Neurosci 14:837649. https:\/\/doi.org\/10.3389\/fnagi.2022.837649","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"11929_CR81","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/ijms25010582","volume":"25","author":"A Drakontaeidi","year":"2024","unstructured":"Drakontaeidi A, Pineda C, Smith JR, Wang Y, Li H, Chen Z et al (2024) Multi-target-directed cinnamic acid hybrids: design, synthesis and biological evaluation for Alzheimer\u2019s disease. Int J Mol Sci 25(1):582. https:\/\/doi.org\/10.3390\/ijms25010582","journal-title":"Int J Mol Sci"},{"key":"11929_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2231661","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, He Y, Teng X, Mi J, Yang J, Wei R, Liu W, Ma Q, Tan Z, Sang Z (2023) Development of novel salicylic acid\u2013donepezil\u2013rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease. J Enzyme Inhib Med Chem. https:\/\/doi.org\/10.1080\/14756366.2023.2231661","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11929_CR83","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1039\/D4SC06762B","volume":"16","author":"J Yoo","year":"2025","unstructured":"Yoo J, Lee J, Ahn B, Han J, Lim MH (2025) Multi-target-directed therapeutic strategies for Alzheimer\u2019s disease: controlling amyloid-\u03b2 aggregation, metal ion homeostasis, and enzyme inhibition. Chem Sci 16:2105\u201335. https:\/\/doi.org\/10.1039\/D4SC06762B","journal-title":"Chem Sci"},{"issue":"6","key":"11929_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060831","volume":"18","author":"EE Katsoulaki","year":"2025","unstructured":"Katsoulaki EE, Dimopoulos D, Hadjipavlou-Litina D (2025) Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegeneration diseases. Pharmaceuticals Basel 18(6):831. https:\/\/doi.org\/10.3390\/ph18060831","journal-title":"Pharmaceuticals Basel"},{"issue":"9","key":"11929_CR85","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/ph17091238","volume":"17","author":"IG El Idrissi","year":"2024","unstructured":"El Idrissi IG, Khallouki F, Bouklouch Y, Bekkouche K et al (2024) Multitarget-directed ligands hitting serotonin receptors: medicinal chemistry efforts and perspectives. Pharmaceuticals 17(9):1238. https:\/\/doi.org\/10.3390\/ph17091238","journal-title":"Pharmaceuticals"},{"issue":"10","key":"11929_CR86","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2174\/0929867328666210512005508","volume":"29","author":"B Kumar","year":"2022","unstructured":"Kumar B, Singh R, Kaur J, Sharma M et al (2022) Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer\u2019s disease. Curr Med Chem 29(10):1757\u2013803. https:\/\/doi.org\/10.2174\/0929867328666210512005508","journal-title":"Curr Med Chem"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11929-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11929-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11929-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:43:32Z","timestamp":1778589812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11929-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11929"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11929-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"749"}}